Showing 4411-4420 of 9719 results for "".
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Novan: Significant Improvement of Genital Warts with SB206https://practicaldermatology.com/news/novan-significant-improvement-of-genital-warts-with-sb206/2458355/Top-line results from Novan Inc.’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV show statistically significant benefits, the company reports. The highest dose tested, SB206 12%, demonstrated a st
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails.
- Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantageshttps://practicaldermatology.com/news/two-new-studies-suggest-bpx-01-topical-minocycline-may-hold-advantages/2458376/Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne vulgaris. The research was at the Skin Disease Edu
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based
- Bob Rhatigan Joins ALASTIN Skincare's Board of Directorshttps://practicaldermatology.com/news/bob-rhatigan-joins-alastin-skincares-board-of-directors/2458384/Bob Rhatigan is joining ALASTIN Skincare™, Inc’s Board of Directors effective December 2016. Mr. Rhatigan most recently served as President and Chief Operating Officer at Alphaeon Corporation. Prior to this, he spent 17 years at Allergan In
- Brenton L. Saunders is Allergan's New Chairman of the Boardhttps://practicaldermatology.com/news/brenton-l-saunders-is-allergans-new-chairman-of-the-board/2458389/Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of
- Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/novan-phase-2b-data-for-sb204-gel-to-be-presented-at-fall-clinical-dermatology-conference/2458396/Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. The presentation wil